Rus Eng
Main / Company's news / GEROPHARM: the results of 2015 - import substitution in dynamics

GEROPHARM: the results of 2015 - import substitution in dynamics

14 March 2016

During the last two years the Russian society began denying many of the imposed stereotypes. In the current conditions, connected with the country’s foreign policy, the idea of a strong local industry acquires a new meaning: today, import substitution is not a goal in itself. It is a means to overcome the country's vulnerability in technology, professional skills and also a means to create and strengthen the country’s competitive advantages.

Today, we have everything for this purpose.For instance, GEROPHARM, one of the leading Russian manufacturers, has accumulated enough competences, which help not only develop corporate science and production, but also expand the drug pipeline with complex biotechnological drugs. Following the results of 2015, against the background of general decline in subsistence consumption in the pharmaceutical market by more than 6%, the company has managed to achieve the maximum revenue growth in its history - 22%, compared to 2014; following the results of the last year, the company’s revenue was about 3 billion rubles. Thus, over the last few years the company has been maintaining the growth rate that outpaces the growth rate of the Russian pharmaceutical market.

Continuing the development in accordance with the long term strategy, the company is expanding its drug pipeline by implementing production technologies of local original drugs andcomplex biotechnological drugs from the segment of biosimilars, generics. With the end of each investment cycle of projects, the company diversifies its pipeline: following the results of 2015, for the first time, genetically engineered insulins of local production (Rinsulin®) have occupied a significant share in the revenue growth from sales - more than 35%. According to IMS Health analytical agency, Rinsulin's share has increased by 3 times, approaching the indicator of 10% in volume terms. At the same time, following the results of the year, in the key regions of the Russian Federation: Moscow, St. Petersburg, the Moscow and Leningrad regions, Bashkortostan, the Rostov region, the Orenburg region and the Crimea - Rinsulin® has occupied from 20% to 60% of the market share depending on the region’s demand.

"Last year was really significant from the point of view of import substitution dynamics," commented on the results in this segment the head of GEROPHARM Group Petr Rodionov. "Local insulins produced by GEROPHARM-Bio are a real successful project in the field of import substitution, which today can be confirmed by the figures: over this period our share has increased almost by 10 times: we supply the market with our drug not only in the form of vials and cartridges but also in the form of syringe-pens.

More importantly, we have managed to increase capacities for the production of local insulin substances – today our plant in the Moscow region can cover 30% of the country's demand. After the commissioning of the second plant within the framework of the pharmaceutical cluster in St. Petersburg our capacities will be enough to cover 100% of insulin demand and develop export. We have all preconditions for this.Let me repeat: there must becritically important technologies in Russia, which can guarantee the availability of vital drugs and social stability."

Today, the company has a considerable number of drugs in the field of diabetology that make up the company’s pipeline: the local substances of analogue drugs lispro, biphasic lispro, glargine were created in 2015, their production technologies were developed on the basis of a full cycle principle; the development of the drugs aspart and degludec is still being carried out. The full pipeline of local analogue insulins will be introduced to the market in 2019, which will significantly reduce the expenses of the state budget on drug provision in the segment of diabetes, the amount of which has exceeded 13 billion rubles by the end of 2015. The volume of the Russian market of gliptins is about 2.5 billion rubles.

GEROPHARM is traditionally one of the leaders in the segment of neurology: following the results of the year, the drug Levetinol® (INN: levetiracetam) has taken the first place among generics both in retail segment and in total sales amount by its INN. A well-known original drug Cortexin® is included into the updated VED list. It is also in TOP 4 list of prescription drugs of local production due to its retail sales amount. The company's pipeline has been expanded with a new generic Recognan® (INN: citicoline) used for the treatment of such diseases like ischemic stroke, post-stroke rehabilitation, acute and recovery stage of traumatic brain injury, cognitive and behavioral impairment associated with neurodegenerative and cerebrovascular diseases. The company produces Recognan® in various forms: ampoules, vials and bags of solution for oral use, which considerably improves the drug’s application properties. The production is carried out at the company’s manufacturing site – GEROPHARM-Bio.

In 2015, GEROPHARM registered the original drug Pineamin®, which opened a new therapeutic area for the company – women's health. Pineamin® – the first injectable drug intended for the treatment of menopausal syndrome with the innovative PPG (Polypeptides of the Pineal Gland) class effect and Anti-age effect. The product is developed for the treatment of neurovegetative disorders in menopausal syndrome in women with contraindications to hormonal replacement therapy (HRT) or in case of its refusal. The drug is available in the form of lyophilisate used to prepare the solution for intramuscular injection in a dose of 10 mg. The drug will be introduced to the market in 2016.

Through the development and introduction of new drugs to the market, GEROPHARM strives to maintain an ongoing dialogue with the medical and patient communities, who have an opportunity to make sure that local drugs are effective, safe and of good quality. And this is the key to success, as the true import substitution is not only the ability to produce drug or get access to the market. It is a general positive result, when doctors confidently prescribe, and patients use drugs of local production without any doubts.

In 2015, in order to enhance corporate communications, the company launched a new version of the official website and opened official pages in popular social networks: Facebook, Instagram, LinkedIn.

The project "My New Page", a unique collection of stories of real insulin-dependent heroes, is the result of cooperation with patient community represented by people with diabetes. Each of them has managed to overcome not only the disease, but also the doubts and fears and has also managed to open a new and happy page in the life. The book was presented to the wide audience in November-December 2015 in the framework of the World Diabetes Day. According to the participants, the project can be considered as one of the most sincere projects, which is not a coincidence, as the main idea of the project – to help people – isconsonant with GEROPHARM’s philosophy.

You are a health care professional?

Go up